MSOS stock forecast, quote, news & analysis

Key Takeaways

• MSOS declined roughly 25% over the past 30 days, retreating from a multi-month high near $5.40 to about $3.91.
• The slide was triggered by a pause in the federal process to reschedule cannabis from Schedule I to Schedule III, reviving uncertainty around Section 280E tax relief.
• The fund's concentrated, swap-based exposure to U.S. multi-state operators (MSOs) amplified the move as major holdings sold off in tandem.
• Over the trailing quarter, MSOS is down roughly 8%, reflecting a volatile, headline-driven trading range rather than a one-way trend.
• The ETF's largest exposures—Trulieve, Curaleaf, and Green Thumb Industries—remain highly sensitive to federal cannabis policy developments.
• For additional context on this ticker, explore Price Targets and Forecast pages to review technical and predictive analytics.
• Discover Trending AI Robots for automated, signal-driven trading strategies across a broad universe of securities.

AdvisorShares Pure US Cannabis ETF (MSOS) Overview and Portfolio Exposure

The AdvisorShares Pure US Cannabis ETF (MSOS) is an actively managed, non-diversified fund that seeks long-term capital appreciation by investing primarily in U.S. companies deriving at least half of their net revenue from the marijuana and hemp business, along with derivatives such as total return swaps that replicate the economic characteristics of those securities. Launched in September 2020, the fund charges a net expense ratio of approximately 0.78% and holds roughly two dozen underlying positions, with assets under management (AUM) near $800 million.

Because many leading U.S. cannabis operators list on Canadian exchanges or over-the-counter (OTC) markets, MSOS relies heavily on swap contracts to gain exposure. Its largest exposures center on Trulieve Cannabis (TRLV), Curaleaf, and Green Thumb Industries, supplemented by smaller positions in Glass House Brands, Verano Holdings, Cresco Labs, and TerrAscend. This concentrated structure makes the fund a pure-play proxy for U.S. cannabis MSOs and leaves it highly correlated with federal regulatory headlines and the tax treatment of the sector.

AdvisorShares Pure US Cannabis ETF (MSOS) Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, MSOS fell approximately 25%, from a closing level near $5.18 to about $3.91. The decline was sharp and concentrated in a matter of sessions rather than gradual, punctuated by elevated trading volume during the initial selloff.

The broader three-month picture is more tempered. Over the trailing quarter, MSOS is down roughly 8%, having traded largely within a range between the low $4 area and the low $5 area. A mid-September rally pushed the fund to a multi-month peak near $5.43 before the regulatory setback reversed those gains. This pattern—episodic surges followed by sharp givebacks—has characterized the fund's recent price behavior and underscores its sensitivity to policy-driven sentiment.

What Drove MSOS Price in the Last 30 Days

The primary catalyst was a procedural pause in the Drug Enforcement Administration's (DEA) effort to reschedule cannabis from Schedule I to Schedule III. A Government Accountability Office (GAO) report raised questions about the process used to reach the rescheduling proposal, prompting an administrative law judge to temporarily halt the proceedings. That rekindled uncertainty over the timeline for ending Section 280E of the tax code, which currently bars cannabis businesses from deducting ordinary operating expenses and drives effective tax rates well above statutory levels.

Because ending Section 280E is central to the earnings and cash-flow outlook for U.S. MSOs, the pause hit the sector broadly. Trulieve, one of MSOS's largest exposures, fell roughly 14% to 16%, while other operators such as Glass House Brands posted double-digit declines. MSOS's concentration in these names translated those losses directly into the fund's net asset value (NAV), amplifying the move relative to broader equity markets. Consolidation activity, including M&A interest involving Canadian operators, continued in the background but was overshadowed by the regulatory setback.

What Drove MSOS Performance Over the Last Quarter

Over the trailing three months, MSOS's performance has been shaped less by company fundamentals than by shifting expectations around federal cannabis policy. Optimism about rescheduling, potential relief from Section 280E, and the prospect of major U.S. exchange uplistings drove intermittent rallies, while procedural delays and lingering legislative gridlock triggered reversals. Institutional positioning has remained cautious, with the sector still dependent on retail and specialized investors.

The quarter's roughly 8% net decline reflects a market caught between improving underlying operator economics and unresolved regulatory risk. Earnings and free cash flow (FCF) for several large MSOs have improved as operators rationalized costs, but those gains have been repeatedly discounted against the backdrop of policy uncertainty.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, and AI-generated signals. Rather than reviewing charts manually, users can set performance characteristics to surface securities matching specific criteria across sectors and market-cap segments. For investors monitoring fast-moving thematic funds like MSOS, the screener offers a structured way to identify related momentum, breakout, and rotation opportunities more efficiently. Explore the platform to refine your research workflow and uncover actionable candidates aligned with your market view.

MSOS ETF Outlook: What Investors Should Watch Next

The most important variable for MSOS remains the trajectory of federal cannabis rescheduling and any legislative action addressing Section 280E. Investors should monitor the rescheduling proceedings, potential reopening of the administrative record, and signals from federal regulators on timing. A shift to Schedule III would meaningfully improve after-tax profitability and cash flow across the fund's holdings.

Beyond policy, attention should focus on the earnings and cash-flow trajectory of Trulieve, Curaleaf, and Green Thumb Industries, particularly their margin trends and capital spending. Progress toward major U.S. exchange uplistings—and the institutional flows and index eligibility that could follow—represents another structural catalyst. Macroeconomic conditions, including interest rates and consumer spending, and persistent competitive pricing pressure within state markets also warrant monitoring. These themes, rather than day-to-day headline moves, are likely to define the fund's direction in the coming months.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations